TC Biopharm announces artificial intelligene initiative with Carnegie Mellon

TC BioPharm announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process. “TC BioPharm is pleased to partner with Carnegie Mellon University as we continue to research cutting-edge solutions for the advancement of the cell therapy industry,” stated Bryan Kobel, CEO of TC BioPharm. “An issue the cell therapy industry faces as a whole is donor variability as well as how to more accurately predict outcomes and responses between donors and patients. Finding a solution for how to select the best donors for allogeneic cell therapies to generate the best product, and also how to match the best cell therapy and donor to the best patient beyond the current HLA matching process, represents a massive opportunity from a market perspective and also would have far-reaching applications for CDMOs and other industry players.”